Fig. 2: On treatment ctDNA dynamics associate with clinical outcomes in the training dataset. | Nature Medicine

Fig. 2: On treatment ctDNA dynamics associate with clinical outcomes in the training dataset.

From: A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Fig. 2

a, On-treatment ctDNA levels as measured by MTM (per milliliter plasma) across longitudinal time points for patients with week 6 radiographic assessments of treatment response of PD (red), SD (purple) and CR/PR (blue). b, KM curves showing OS for patients with SD (purple) versus PR (green) as determined at the week 6 radiographic assessment of treatment response. A univariable Cox proportional-hazards model was used to estimate HR and log-rank test to report P value. c, KM curves showing OS for patients with C3D1 ctDNA levels below the LOD of the assay (<1 MTM, ctDNA low risk, blue) versus near or above the LOD (≥1 MTM, ctDNA high risk, red). A univariable Cox proportional-hazards model was used to estimate HR and log-rank test to report P value. The exact P value for ‘P < 0.001’ is 0.00029871. d,e, KM curves showing OS for patients with SD (d) and PR (e) at week 6 who are further risk stratified by ctDNA levels at C3D1. A univariable Cox proportional-hazards model was used to estimate HR and log-rank test to report P value. MTM, mean tumor molecules.

Back to article page